Profile: Nuvera Biosciences, Inc. is focused on developing novel molecular diagnostics that make a significant impact on cancer care by improving detection techniques and treatment selection in cancer. We focus on cancer molecular research, cancer care, and drug trials. We offer a broad portfolio of clinically validated tests for therapy response, drug resistance and prognosis based on efficient molecular testing platforms. We cater to treatments in breast cancer leading to higher response from chemotherapy & endocrine therapy. We have developed a unique measure of residual cancer burden (RCB) from routine pathologic parameters such as primary tumor size, cellularity and lymph node status. Treatment sensitivity is based on ranges of residual cancer that can help cover the entire response spectrum using a continuous index. With this measure, high responders are captured that would be otherwise classified as residual cancer.